A Double-blind, Placebo-controlled, Randomised, Multi-centre, 3-way Cross-over, Single-dose Phase II Study to Investigate the Local and Systemic Effects of Inhaled AZD8683 in Patients With Chronic Obstructive Pulmonary Disease (COPD).
Phase of Trial: Phase II
Latest Information Update: 24 Jan 2014
At a glance
- Drugs AZD 8683 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms Cricket
- Sponsors AstraZeneca
- 11 May 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 22 Oct 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 28 Sep 2010 New trial record